

AMENDMENT UNDER 37 C.F.R. § 1.111
Application No.: 10/578,839

Attorney Docket No.: Q94769

Please delete the present Abstract of the Disclosure.

Please add the following new Abstract of the Disclosure:

Abstract of the Disclosure

The inventive chimeric ligand in the form of a fusion polypeptide of a single-chain antibody specific for Tag-72 surface antigen and GaLV envelope glycoprotein shows high transduction efficiency to cancer cells, specifically infects target cells and efficiently delivers a therapeutic gene. Accordingly, the inventive chimeric ligand can be effectively used for gene therapy to inhibit tumor growth and metastasis.